Dyadic International (NASDAQ:DYAI) is moving from technology-platform development toward commercial execution, with multiple products entering the market through its own channels and partnerships, President and Chief Operating Officer Joe Hazelton said at the Lytham Partners Fall 2026 Investor Conference.
Hazelton said the company is applying its fungal gene-expression platforms to produce proteins and enzymes for three core markets: life sciences, food and nutrition, and bioindustrial applications. He characterized life sciences as the company’s primary near-term commercial focus, citing demand for non-animal-derived proteins used in cell and gene therapy, diagnostics, cell culture media and related applications.
Life sciences takes priority
Hazelton highlighted molecular biology reagents and cell culture media components as areas of focus. These include DNase I, an enzyme used in cell and gene therapy, diagnostics and medical-equipment cleaning, as well as albumin, transferrin and growth factors used in cell culture.
According to Hazelton, DNase I is used to cleave DNA and can be an input in cell and gene therapy products and manufacturing workflows. He said recombinant production may offer benefits including supply sustainability, batch-to-batch consistency and reduced potential exposure to viruses or pathogens associated with animal- or plant-derived inputs.
The company uses two expression platforms for different markets. Its C1 platform is aimed at producing complex, high-value proteins for life-science and biopharmaceutical uses, while its Dapibus platform is designed for higher-yield, lower-cost production of proteins for food, nutrition and bioindustrial markets, Hazelton said.
Hazelton said Dyadic’s products are being evaluated for workflows spanning cell and gene therapy, diagnostics and research and development. He expects recurring demand to develop as products become incorporated into customers’ workflows, while acknowledging that product adoption and launch activity may be uneven initially.
Partners support market access
Dyadic has established several commercialization models, including direct product sales, distribution arrangements, licensing and profit-sharing partnerships, Hazelton said. He said the company is no longer relying solely on licensing and grant revenue and has begun recording initial product sales.
Integrated BioTherapeutics, or IBT, has six products manufactured using Dyadic’s gene-expression technology available on its website, according to Hazelton. He identified products including DNase I, transferrin, growth factors and alpha-lactalbumin. Hazelton said the relationship gives Dyadic broader access to the market than it could reach independently.
The company has also licensed bovine chymosin to Inzymes, which Hazelton said has commercialized and is selling the product in the food and nutrition market.
In addition, Dyadic has a profit-sharing arrangement with Proliant Health & Biologicals. Hazelton said Proliant is selling recombinant human albumin under the AlbuFree DX name for research applications and has announced plans for two additional recombinant human albumin products targeting cell and gene therapy and cell culture media markets.
Additional opportunities in development
Hazelton said Dyadic has developed two strains capable of producing hyaluronidase, an enzyme used in biopharmaceutical drug delivery and cosmetic medicine. He said the company believes its platform can improve manufacturing economics for the enzyme and can glycoengineer protein structures to be humanized. However, he noted that Dyadic does not have the resources to advance every potential program on its own.
The company also sees midterm opportunities in food and nutrition and bioindustrial applications. Hazelton cited partnerships with BRIG BIO and Fermbox Bio, as well as the commercial launch of EN3ZYME by Fermbox Bio. While Dyadic expects revenue from those segments, he said life sciences remains the company’s central near-term priority.
Looking ahead, Hazelton said 2025 centered on creating product portfolios and enabling products, while 2026 has focused on product launches and gaining commercial traction. The next stage, he said, will involve expanding distribution, broadening the product portfolio and identifying strategic partners.
Dyadic also plans to continue pursuing non-dilutive pharmaceutical partnerships, including work with the Gates Foundation and CEPI, Hazelton said. He said such collaborations can validate the company’s platform for biopharmaceutical use without diverting attention from near-term commercial revenue efforts.
About Dyadic International (NASDAQ:DYAI)
Dyadic International, Inc is a biotechnology company that develops microbial-based technologies for producing proteins and other biological materials. Its platforms are designed to enable the cost-effective development and manufacture of vaccines, therapeutic proteins, enzymes, and other biologic products.
The company’s technology portfolio includes the C1 protein-production platform, which uses a proprietary fungal microorganism to produce recombinant proteins, and additional microbial expression systems intended to support applications in biopharmaceuticals, animal health, food and nutrition, and industrial biotechnology.
